Literature DB >> 17303514

Managing high-risk breast cancer.

Frances M Palmieri1, Edith A Perez.   

Abstract

OBJECTIVES: To identify breast cancer patients at high risk for recurrence. To describe current evidence for clinical management of early and locally advanced breast cancer and integrate this knowledge into nursing practice. DATA SOURCES: Articles, abstracts, and practice guidelines.
CONCLUSION: Recent clinical trials have integrated the biology of breast cancer into individualized systemic therapy. Risk-adjusted treatment is driven by the addition of taxane therapy to systemic therapy, aromatase inhibitors, and trastuzumab into adjuvant therapy strategies. IMPLICATIONS FOR NURSING PRACTICE: The decision to initiate systemic adjuvant therapy requires knowledge of risk of relapse, integration of evidence from clinical trials, and facilitation of patient decision-making.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17303514      PMCID: PMC1880870          DOI: 10.1016/j.soncn.2006.11.005

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  37 in total

Review 1.  The National Institutes of Health Consensus Development Conference: Adjuvant Therapy for Breast Cancer. Bethesda, Maryland, USA. November 1-3, 2000. Proceedings.

Authors: 
Journal:  J Natl Cancer Inst Monogr       Date:  2001

2.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

Review 4.  Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.

Authors:  Dina K Tack; Frances M Palmieri; Edith A Perez
Journal:  Oncology (Williston Park)       Date:  2004-10       Impact factor: 2.990

5.  Cardiac dysfunction in the trastuzumab clinical trials experience.

Authors:  Andrew Seidman; Clifford Hudis; Mary Kathryn Pierri; Steven Shak; Virginia Paton; Mark Ashby; Maureen Murphy; Stanford J Stewart; Deborah Keefe
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.

Authors:  S Paik; J Bryant; C Park; B Fisher; E Tan-Chiu; D Hyams; E R Fisher; M E Lippman; D L Wickerham; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

8.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

9.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

10.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Authors:  S Paik; R Hazan; E R Fisher; R E Sass; B Fisher; C Redmond; J Schlessinger; M E Lippman; C R King
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

View more
  1 in total

1.  Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

Authors:  Michele Y Halyard; Thomas M Pisansky; Amylou C Dueck; Vera Suman; Lori Pierce; Larry Solin; Larry Marks; Nancy Davidson; Silvana Martino; Peter Kaufman; Leila Kutteh; Shaker R Dakhil; Edith A Perez
Journal:  J Clin Oncol       Date:  2009-04-06       Impact factor: 44.544

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.